论文部分内容阅读
为选择最佳的预处理方案和造血干细胞来源,作者对18例恶性淋巴瘤[10例非霍奇金淋巴瘤(NHL),8例霍奇金淋巴瘤(HL)]患者采用大剂量CVB(环磷酰胺4×1.5g/m~2,鬼臼乙叉甙4×250～400mg/m~2,卡氯芥4×150～200mg/m~2)作预处理后,13例作自身外周血干细胞移植(PBSCT),5例自体骨髓移植(ABMT)。NHL患者中8例属进展期(Ⅳ期7例,Ⅲ期1例),属B期3例。包括低度恶性1例,中度6例,高度3例。HL患者中7例属进展期(Ⅲ期5例,Ⅳ期2例),属B期5例。所有患者经
In order to choose the best preconditioning regimen and the source of hematopoietic stem cells, the authors used a high-dose CVB (n = 10) for 18 patients with malignant lymphoma [10 non-Hodgkin’s lymphoma (NHL) and 8 Hodgkin’s lymphoma (HL) Cyclophosphamide 4 × 1.5g / m ~ 2, etoposide 4 × 250 ~ 400mg / m ~ 2, card chlorine mustard 4 × 150 ~ 200mg / m ~ 2) for pretreatment, 13 cases of its own peripheral Blood stem cell transplantation (PBSCT), 5 autologous bone marrow transplantation (ABMT). Among NHL patients, 8 cases were advanced (7 in stage Ⅳ and 1 in stage Ⅲ), and 3 were in stage B. Including 1 case of low grade, 6 cases of moderate, 3 cases of height. Seven of the HL patients were advanced (5 in stage Ⅲ, 2 in stage Ⅳ), and 5 in stage B. All patients by